CASE PRESENTATIONSColistin-resistant Acinetobacter baumannii a case report and literature reviewJaidane, Nadia; Chaouech, Cherifa; Messaoudi, Aziza; Boujaafar, Noureddine; Bouallegue, OlfaAuthor Information Emerging Bacterial Resistance and Safety of Care (UR 12 SP 37), Department of Microbiology, University Hospital of Sahloul, Sousse, Tunisia. Correspondence to Nadia Jaidane, Emerging Bacterial Resistance and Safety of Care (UR 12 SP 37), Department of Microbiology, University Hospital of Sahloul, Rte de ceinture, 4054 Sousse, Tunisia. Tel: +216 98684541; fax: +216 73367451; e-mail: Nadia.firstname.lastname@example.org Received 18 October, 2014 Revised 6 November, 2014 Accepted 6 November, 2014 Reviews in Medical Microbiology: April 2015 - Volume 26 - Issue 2 - p 78-83 doi: 10.1097/MRM.0000000000000029 Buy Metrics Abstract Acinetobacter baumannii has emerged as one of the most troublesome pathogens in healthcare settings. Its clinical significance has been propelled by its remarkable ability in acquiring resistance to almost all available antibiotics. Colistin (COL), an old antibiotic, has become the last resort of treatment for multidrug-resistant A. baumannii. Unfortunately, COL heteroresistance and COL resistance have been reported all over the world in A. baumannii. Being the first report of COL-resistant A. baumannii from our institution, we have tried to explore the prolonged stay in the ICU of the patient and also briefly reviewed the literature. However, well designed trials of new therapeutic approaches are certainly required. Copyright © Wolters Kluwer Health, Inc. All rights reserved.